/
CDNA
$29.28+$0.46 (+1.60%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.5B
52M shares
52-week range
$10.96 – $29.58
98% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-62.24
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $76.6M | $127.1M | $192.2M | $296.4M | $321.8M | $280.3M | $333.8M | $379.8M |
| Cost of revenue | $33.0M | $45.5M | $63.1M | $97.4M | $112.2M | $102.0M | $109.6M | $125.4M |
| Gross profit | $43.6M | $81.6M | $129.1M | $199.0M | $209.6M | $178.3M | $224.2M | $254.4M |
| Gross margin | 56.9% | 64.2% | 67.2% | 67.1% | 65.1% | 63.6% | 67.2% | 67.0% |
| R&D | $14.5M | $30.7M | $48.9M | $76.5M | $90.4M | $81.9M | $72.4M | $71.4M |
| Operating income | −$15.6M | −$24.5M | −$22.5M | −$29.7M | −$77.2M | −$203.4M | $40.8M | −$21.0M |
| EBITDA | −$11.4M | −$17.4M | −$8.2M | −$20.2M | −$60.2M | −$84.9M | −$34.0M | −$667.0K |
| Net income | −$46.8M | −$22.0M | −$18.7M | −$30.7M | −$76.6M | −$190.3M | $52.5M | −$21.4M |
| Net margin | -61.1% | -17.3% | -9.7% | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% |
| EPS (diluted) | -1.31 | -0.52 | -0.40 | -0.59 | -1.44 | -3.54 | 0.93 | -0.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $456M | $0.93 | $0.90–$0.96 | 3 |
| 2027 | $481M | $1.13 | $1.09–$1.16 | 3 |
| 2028 | $507M | $1.53 | $1.47–$1.56 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
CareDx, Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
www.caredx.com- Employees
- 765
- IPO / List date
- Jul 17, 2014
- HQ
- BRISBANE, CA
Held by traders on TradeandTell
No one on the platform currently holds CDNA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,184,398 | $20.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CDNA yet.
